Cargando…
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
Hepatocellular carcinoma (HCC) is the most common malignancy worldwide, and is especially common in China. A total of 70%–80% of patients are diagnosed at an advanced stage and can receive only palliative care. Sorafenib has been the standard of care for a decade, and promising results for regorafen...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394775/ https://www.ncbi.nlm.nih.gov/pubmed/30819826 http://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s01 |